封面
市场调查报告书
商品编码
1098619

脊髓性肌萎缩症的市场规模、占有率、展望、机会 (2022年~2030年):各类型、治疗方法、年龄层、给药途径、通路、地区

Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格
简介目录

主要企业的产品上市增加促进在预测期间内的脊髓性肌萎缩症市场成长。还有主要企业的联盟、合作等无机性策略的采用增加也预计成为在预测期间内的市场成长的原动力。

本报告提供全球脊髓性肌萎缩症的市场调查,市场定义和概要,市场成长的各种影响因素分析,法律制度,技术趋势,市场规模的变化、预测,各种区分、各地区/主要国家的明细,竞争环境,主要企业简介等彙整资讯。

目录

第1章 调查目的、前提条件

第2章 市场概要

第3章 市场动态、法规、趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 收购、联盟
  • 技术的进步
  • 法规情境
  • PEST分析
  • 产品销售

第4章 全球脊髓性肌萎缩症市场:COVID-19的影响

  • 整体影响
  • 政府的举措
  • COVID-19:对市场的影响

第5章 全球脊髓性肌萎缩症市场:各类型

  • 概要
  • 类型I
  • 类型II
  • 类型III
  • 类型IV

第6章 全球脊髓性肌萎缩症市场:各治疗

  • 概要
  • 基因治疗
  • 缓解疾病药

第7章 全球脊髓性肌萎缩症市场:各年龄

  • 概要
  • 儿童
  • 成人

第8章 全球脊髓性肌萎缩症市场:各给药途径

  • 概要
  • 口服
  • 注射

第9章 全球脊髓性肌萎缩症市场:各销售管道

  • 概要
  • 医院药局
  • 零售药局
  • 线上药局

第10章 全球脊髓性肌萎缩症市场:各地区

  • 北美
  • 南美
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第11章 竞争情形

  • Biogen
  • CYTOKINETICS
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

第12章 Section

简介目录
Product Code: CMI1920

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

  • This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

  • Global Spinal Muscular Atrophy Market, By Type:
  • Type I
  • Type II
  • Type III
  • Type IV
  • Global Spinal Muscular Atrophy Market, By Treatment:
  • Gene Therapy
  • Disease-modifying drugs
  • Global Spinal Muscular Atrophy Market, By Age Group:
  • Infant
  • Adult
  • Global Spinal Muscular Atrophy Market, By Route of Administration:
  • Oral
  • Injectables
  • Global Spinal Muscular Atrophy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Spinal Muscular Atrophy Market, By Region:
  • North America
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • Biogen
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • CYTOKINETICS
  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Treatment
    • Market Snapshot, By Age
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Acquisitions and Partnerships Scenario
  • Technological Advancements
  • Regulatory Scenario
  • PEST Analysis
  • Product Launches

4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Spinal Muscular Atrophy Market, By Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Type I
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type II
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type III
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type IV
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Treatment, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Gene Therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Disease-modifying drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Age, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Infant
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Injectables
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

10. Global Spinal Muscular Atrophy Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

11. Competitive Landscape

  • Biogen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CYTOKINETICS
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Genentech, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PTC Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ionis Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Chugai Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NMD PHARMA A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

12. Section

  • Research Methodology
  • About Us